HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions such as long-haul COVID-19. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth factor-β and stimulate immune cells, targeting senescent cells and the SASP factors they secrete. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, and others.
Mã chứng khoánHCWB
Tên công tyHCW Biologics Inc
Ngày IPOJul 20, 2021
Giám đốc điều hànhDr. Hing C. Wong, Ph.D.
Số lượng nhân viên36
Loại chứng khoánOrdinary Share
Kết thúc năm tài chínhJul 20
Địa chỉ2929 N Commerce Pkwy
Thành phốMIRAMAR
Sàn giao dịch chứng khoánNASDAQ Capital Market Consolidated
Quốc giaUnited States of America
Mã bưu điện33025
Điện thoại19548422024
Trang webhttps://hcwbiologics.com/
Mã chứng khoánHCWB
Ngày IPOJul 20, 2021
Giám đốc điều hànhDr. Hing C. Wong, Ph.D.
Tổng cộng
0.00
USD đã được phân phối dưới dạng cổ tức trong 5 năm qua.

Không có dữ liệu